Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

JAMA

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
JAMA|May 5, 2011
What next for QALYs?Peter J Neumann
JAMA|May 26, 2018
QALYs in 2018-Advantages and ConcernsPeter J Neumann, Joshua T Cohen
JAMA|April 18, 2023
Cost-effectiveness Thresholds Used by Study Authors, 1990-2021Peter J Neumann, David D Kim
JAMA|January 22, 2003
Direct-to-consumer advertising and shared liability for pharmaceutical manufacturersMichelle M Mello, Meredith Rosenthal, Peter J Neumann
JAMA|December 29, 2016
Updated Recommendations for Cost-effectiveness Studies-ReplyGillian D Sanders, Peter J Neumann, Louise B Russell
JAMA|September 29, 2025
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene TherapiesJames D Chambers, Julia A Rucker, Daniel E Enright, et al.
JAMA|July 23, 2002
Long-term persistence in use of statin therapy in elderly patientsJoshua S Benner, Robert J Glynn, Helen Mogun, et al.
JAMA|May 20, 2020
Coverage for Biosimilars vs Reference Products Among US Commercial Health PlansJames D Chambers, Rachel C Lai, Nikoletta M Margaretos, et al.
JAMA|September 14, 2016
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and MedicineGillian D Sanders, Peter J Neumann, Anirban Basu, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
JAMA|May 5, 2011
What next for QALYs?Peter J Neumann
JAMA|May 26, 2018
QALYs in 2018-Advantages and ConcernsPeter J Neumann, Joshua T Cohen
JAMA|April 18, 2023
Cost-effectiveness Thresholds Used by Study Authors, 1990-2021Peter J Neumann, David D Kim
JAMA|January 22, 2003
Direct-to-consumer advertising and shared liability for pharmaceutical manufacturersMichelle M Mello, Meredith Rosenthal, Peter J Neumann
JAMA|December 29, 2016
Updated Recommendations for Cost-effectiveness Studies-ReplyGillian D Sanders, Peter J Neumann, Louise B Russell
JAMA|September 29, 2025
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene TherapiesJames D Chambers, Julia A Rucker, Daniel E Enright, et al.
JAMA|July 23, 2002
Long-term persistence in use of statin therapy in elderly patientsJoshua S Benner, Robert J Glynn, Helen Mogun, et al.
JAMA|May 20, 2020
Coverage for Biosimilars vs Reference Products Among US Commercial Health PlansJames D Chambers, Rachel C Lai, Nikoletta M Margaretos, et al.
JAMA|September 14, 2016
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and MedicineGillian D Sanders, Peter J Neumann, Anirban Basu, et al.
Pageof 1